683 related articles for article (PubMed ID: 25537246)
1. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
Hu Z; Liu X; Li L; Jia C; Li D; Liu R
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
[TBL] [Abstract][Full Text] [Related]
2. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
3. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age.
Chen Y; Wang X; Li L; Lu S; Zhang Z
BMC Pregnancy Childbirth; 2020 Dec; 20(1):776. PubMed ID: 33317474
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal abnormalities and adverse pregnancy outcome with maternal serum second trimester triple screening test for fetal Down syndrome in 4,860 Chinese women.
Xia YP; Zhu MW; Li XT; Zhou HP; Wang J; Lv JX; Zhong N
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 38(1):49-52. PubMed ID: 16415966
[TBL] [Abstract][Full Text] [Related]
5. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
6. [Serum marker screening during the second trimester for prenatal diagnosis and predicting pregnancy outcome].
Yang L; Zhao L; Jiang J; Liu J; Tao H; Wang J; Wu J
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jul; 35(7):1059-62, 1072. PubMed ID: 26198962
[TBL] [Abstract][Full Text] [Related]
7. Integrating multiple of the median values of serological markers with the risk cut-off value in Down syndrome screening.
Zhou Y; Du Y; Zhang B; Wang L
Biosci Trends; 2018; 12(6):613-619. PubMed ID: 30674761
[TBL] [Abstract][Full Text] [Related]
8. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
9. Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21.
Borrell A; Mercade I; Casals E; Borobio V; Seres A; Soler A; Fortuny A; Cuckle H
Ultrasound Obstet Gynecol; 2007 Dec; 30(7):941-5. PubMed ID: 18000942
[TBL] [Abstract][Full Text] [Related]
10. [The value of maternal first and second trimester serum data of β-hCG, PAPP-A, AFP and uE3 in the prediction of preeclampsia].
Gu W; Lin J; Hou Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):101-7. PubMed ID: 25877605
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of hCG and unconjugated oestriol in prenatal diagnosis of trisomy 18.
Leporrier N; Herrou M; Herlicoviez M; Leymarie P
Br J Obstet Gynaecol; 1996 Apr; 103(4):335-8. PubMed ID: 8605130
[TBL] [Abstract][Full Text] [Related]
13. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
14. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Cuckle HS; van Lith JM
Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of adverse pregnancy outcomes and a high risk serum screen for Down syndrome in the second trimester].
Hu XY; Bian XM; Jiang YL; Liu SY
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):427-30. PubMed ID: 22932108
[TBL] [Abstract][Full Text] [Related]
16. The use of free beta-hCG in antenatal screening for Down's syndrome.
Wald N; Densem J; Stone R; Cheng R
Br J Obstet Gynaecol; 1993 Jun; 100(6):550-7. PubMed ID: 7687460
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18.
Chen Y; Chen Y; Ning W; Zhang W; Li L; Wang X; Yin Y; Zhang H
Sci Rep; 2022 Aug; 12(1):13605. PubMed ID: 35948592
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free beta-subunit (free beta hCG).
Sancken U; Bahner D
Fetal Diagn Ther; 2003; 18(2):122-7. PubMed ID: 12576748
[TBL] [Abstract][Full Text] [Related]
19. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
[TBL] [Abstract][Full Text] [Related]
20. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
